Time course of 75%–100% efficacy response of adjunctive brivaracetam

Background Time to sustained seizure frequency reduction can provide clinically meaningful epilepsy outcomes. Aims of the Study To examine the time course of brivaracetam (BRV) efficacy in adults with focal seizures and focal to bilateral tonic‐clonic seizures (FBTCS). Methods Post hoc analysis of d...

Full description

Saved in:
Bibliographic Details
Published in:Acta neurologica Scandinavica 2020-08, Vol.142 (2), p.175-180
Main Authors: Klein, Pavel, Laloyaux, Cédric, Elmoufti, Sami, Gasalla, Teresa, Martin, Melinda S.
Format: Article
Language:English
Subjects:
antiepileptic drugs
Clinical
Clinical trials
Convulsions & seizures
Epilepsy
focal epilepsy
focal to bilateral tonic‐clonic seizures
partial‐onset seizures
Seizures
sustained seizure reduction
Titration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Time to sustained seizure frequency reduction can provide clinically meaningful epilepsy outcomes. Aims of the Study To examine the time course of brivaracetam (BRV) efficacy in adults with focal seizures and focal to bilateral tonic‐clonic seizures (FBTCS). Methods Post hoc analysis of data pooled from three randomized controlled trials of oral adjunctive BRV in adults with epilepsy. Patients with focal epilepsy and a subpopulation with FBTCS receiving BRV 50, 100, or 200 mg/d (initiated without up‐titration) or placebo for 12 weeks were analyzed for time to sustained ≥75%, ≥90%, and 100% seizure reduction without interruption from first day until trial ends. Results Evaluation included 1160 patients with focal seizures, including 352 patients with FBTCS. Sustained ≥75%, ≥90%, and 100% response in focal seizures was higher from day 1 for BRV 100 and 200 mg/d vs placebo (P 
ISSN:0001-6314
1600-0404
DOI:10.1111/ane.13287